| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938aeb28275a6960545835cfa8454a44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3662ce5995dada5ea3d9873552592af0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c930c1a3fcc9a93dc304ab4a77bd0ea3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
2017-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42fe627ecbf363e63c5c4b3cc17b9278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90bfc61939706a02d5d0b02970689c25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f8d119702939cdae478a86070f9854e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e69d248fb1213800ceab6a2778d8727 |
| publicationDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019292259-A1 |
| titleOfInvention |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| abstract |
The disclosure relates to methods and pharmaceutical compositions for the treatment of non-small cell lung cancer (NSCLC) that coexists with chronic obstructive pulmonary disease (COPD). In particular, the disclosure relates to a method of treating non-small cell lung cancer (NSCLC) in a patient suffering from chronic obstructive pulmonary disease (COPD) comprising administering to the patient a therapeutically effective amount of an immune checkpoint inhibitor such as is a multispecific antibody comprising at least one binding site that specifically binds to a PD-1 molecule and at least one binding site that specifically binds to a TIM-3 molecule. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020264165-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021123920-A1 |
| priorityDate |
2016-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |